Vitateq Biotechnology GmbH
History & Background
Vitateq Biotechnology GmbH was founded in 2000 as research-driven spin-off company of Innsbruck Medical University, Innsbruck, Austria. Prof. Hans Dieplinger, the founder, has longlasting scientific experience in the genetics, metabolism and epidemiology of major risk factors related to cardiovascular disease which is still the number 1 killer worldwide. Numbers are particularly high in industrialised world areas, but are also drastically increasing in developing countries. Vitateq’s research has focused in recent years on afamin (Fig.1), a novel promising blood biomarker for metabolic syndrome and related diseases such as diabetes and obesity. In addition, afamin was also discovered as tumor marker for male and female reproductive organ cancers.
Products & Technology
• Proteomic technologies for the qualitative and quantitative analyses of biomarkers.
• Generation and characterisation of specific monoclonal antibodies against human afamin.
• Protein expression and purification technologies for structure/functional analyses.
• Animal and cell culture models for research in the above- named disorders incl. new treatment approaches.
• Afamin-immunoassay (ELISA) for the early diagnosis of metabolic syndrome and related cardiovascular diseases, cardiovascular complications during pregnancy
and ovarian carcinoma.
• Afamin ELISA is already commercially available.
• Quantification of the human plasma vitamin E-binding protein afamin by means of ELISA (Fig.2) for early detection
of modern-day cardiovascular diseases (metabolic
syndrome, diabetes, obesity, heart attacks, gestational
diabetes, etc), as well as certain forms of cancer affecting reproductive organs (ovarian and testicular carcinoma).
• Afamin is highly significantly associated with the prevalence and incidence of metabolic syndrome, as shown in 3 large, independent population-based cohorts.
• Preliminary data from transgenic mice overexpressing human afamin reveal a metabolic-syndrome-like phenotype, therefore support findings in human
populations and suggest causality of afamin’s role in the observed phenotype.
• To date more than 10,000 patient samples examined, documented in numerous international publications and patents.
Innsbruck Medical University (Division of Genetic Epidemiology, several university hospitals), numerous research partners, both in Austria and abroad (academic and industrial), industrial partners for commercialisation, marketing and distribution of afamin immunoassays.